खोज परिणाम - KRISTELEIT, REBECCA

परिणाम को परिष्कृत करें
  1. 1
    Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10

    Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10 द्वारा Drew, Yvette, Kristeleit, Rebecca S., Oaknin, Ana, Ray‐Coquard, Isabelle, Haris, Noor Md., Swisher, Elizabeth M.

    प्रकाशित 2019
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  2. 2
    COST-EFFECTIVENESS OF NIRAPARIB, RUCAPARIB, AND OLAPARIB FOR TREATMENT OF PLATINUM-RESISTANT, RECURRENT OVARIAN CARCINOMA

    COST-EFFECTIVENESS OF NIRAPARIB, RUCAPARIB, AND OLAPARIB FOR TREATMENT OF PLATINUM-RESISTANT, RECURRENT OVARIAN CARCINOMA द्वारा WOLFORD, JULIET E., BAI, JIARU, MOORE, KATHLEEN N., KRISTELEIT, REBECCA, MONK, BRADLEY J., TEWARI, KRISHNANSU S.

    प्रकाशित 2020
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  3. 3
    A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors

    A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors द्वारा Spicer, James, Irshad, Sheeba, Ang, Joo Ern, Enting, Deborah, Kristeleit, Rebecca, Uttenreuther-Fischer, Martina, Pemberton, Karine, Pelling, Katy, Schnell, David, de Bono, Johann

    प्रकाशित 2016
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  4. 4
    Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy

    Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy द्वारा Milani, Andrea, Kristeleit, Rebecca, McCormack, Mary, Raja, Fharat, Luvero, Daniela, Widschwendter, Martin, MacDonald, Nicola, Mould, Tim, Olatain, Adeola, Hackshaw, Allan, Ledermann, Jonathan A

    प्रकाशित 2017
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  5. 5
    Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts

    Noninvasive Magnetic Resonance Spectroscopic Pharmacodynamic Markers of a Novel Histone Deacetylase Inhibitor, LAQ824, in Human Colon Carcinoma Cells and Xenografts द्वारा Chung, Yuen-Li, Troy, Helen, Kristeleit, Rebecca, Aherne, Wynne, Jackson, L Elizabeth, Atadja, Peter, Griffiths, John R, Judson, Ian R, Workman, Paul, Leach, Martin O, Beloueche-Babari, Mounia

    प्रकाशित 2008
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  6. 6
    An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials

    An Inflammation Based Score Can Optimize the Selection of Patients with Advanced Cancer Considered for Early Phase Clinical Trials द्वारा Pinato, David J., Stavraka, Chara, Flynn, Michael J., Forster, Martin D., O'Cathail, Séan M., Seckl, Michael J., Kristeleit, Rebecca S., Olmos, David, Turnbull, Samantha J., Blagden, Sarah P.

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  7. 7
    Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies

    Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies द्वारा Osborn, Gabriel, Stavraka, Chara, Adams, Rebecca, Sayasneh, Ahmad, Ghosh, Sharmistha, Montes, Ana, Lacy, Katie E, Kristeleit, Rebecca, Spicer, James, Josephs, Debra H, Arnold, James N, Karagiannis, Sophia N

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  8. 8
    Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study

    Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study द्वारा Kristeleit, Rebecca, Moreno, Victor, Boni, Valentina, Guerra, Eva M, Kahatt, Carmen, Romero, Ignacio, Calvo, Emiliano, Basté, Neus, López-Vilariño, José A, Siguero, Mariano, Alfaro, Vicente, Zeaiter, Ali, Forster, Martin

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  9. 9
    Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

    Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors द्वारा Shapiro, Geoffrey I., Kristeleit, Rebecca S., Burris, Howard A., LoRusso, Patricia, Patel, Manish R., Drew, Yvette, Giordano, Heidi, Maloney, Lara, Watkins, Simon, Goble, Sandra, Jaw‐Tsai, Sarah, Xiao, Jim J.

    प्रकाशित 2018
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  10. 10
    First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors

    First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors द्वारा Brunetto, André T., Ang, Joo Ern, Lal, Rohit, Olmos, David, Molife, L. Rhoda, Kristeleit, Rebecca, Parker, Ann, Casamayor, Isabel, Olaleye, Muyibat, Mais, Anna, Hauns, Bernhard, Strobel, Vera, Hentsch, Bernd, de Bono, Johann S.

    प्रकाशित 2013
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  11. 11
    Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

    Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours द्वारा Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca

    प्रकाशित 2019
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  12. 12
    Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

    Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours द्वारा Bono, Petri, Massard, Christophe, Peltola, Katriina J, Azaro, Analía, Italiano, Antoine, Kristeleit, Rebecca S, Curigliano, Giuseppe, Lassen, Ulrik, Arkenau, Hendrik-Tobias, Hakulinen, Pasi, Garratt, Chris, Ikonen, Tarja, Mustonen, Mika V J, Rodon, Jordi A

    प्रकाशित 2020
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  13. 13
    Detection of circulating tumour cell clusters in human glioblastoma

    Detection of circulating tumour cell clusters in human glioblastoma द्वारा Krol, Ilona, Castro-Giner, Francesc, Maurer, Martina, Gkountela, Sofia, Szczerba, Barbara Maria, Scherrer, Ramona, Coleman, Niamh, Carreira, Suzanne, Bachmann, Felix, Anderson, Stephanie, Engelhardt, Marc, Lane, Heidi, Evans, Thomas Ronald Jeffry, Plummer, Ruth, Kristeleit, Rebecca, Lopez, Juanita, Aceto, Nicola

    प्रकाशित 2018
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  14. 14
    Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

    Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment द्वारा Rolfo, Christian, Isambert, Nicolas, Italiano, Antoine, Molife, L. Rhoda, Schellens, Jan H.M., Blay, Jean‐Yves, Decaens, Thomas, Kristeleit, Rebecca, Rosmorduc, Olivier, Demlova, Regina, Lee, Myung‐Ah, Ravaud, Alain, Kopeckova, Katerina, Learoyd, Maria, Bannister, Wendy, Locker, Gershon, de Vos‐Geelen, Judith

    प्रकाशित 2020
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  15. 15
    Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

    Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable... द्वारा Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana

    प्रकाशित 2022
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  16. 16
    First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors

    First-in-human Phase I study of Pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors द्वारा Sarker, Debashis, Ang, Joo Ern, Baird, Richard, Kristeleit, Rebecca, Shah, Krunal, Moreno, Victor, Clarke, Paul A., Raynaud, Florence I., Levy, Gallia, Ware, Joseph A, Mazina, Kathryn, Lin, Ray, Wu, Jenny, Fredrickson, Jill, Spoerke, Jill M, Lackner, Mark R, Yan, Yibing, Friedman, Lori S., Kaye, Stan B., Derynck, Mika K., Workman, Paul, de Bono, Johann S.

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  17. 17
    ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

    ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as mainten... द्वारा Monk, Bradley J, Coleman, Robert L, Fujiwara, Keiichi, Wilson, Michelle K, Oza, Amit M, Oaknin, Ana, O’Malley, David M, Lorusso, Domenica, Westin, Shannon N, Safra, Tamar, Herzog, Thomas J, Marmé, Frederik, N Eskander, Ramez, Lin, Kevin K, Shih, Danny, Goble, Sandra, Grechko, Nikolay, Hume, Stephanie, Maloney, Lara, McNeish, Iain A, Kristeleit, Rebecca S

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  18. 18
    Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours

    Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours द्वारा Kristeleit, Rebecca, Evans, Jeffry, Molife, L. Rhoda, Tunariu, Nina, Shaw, Heather, Slater, Sarah, Haris, Noor R. Md, Brown, Nicholas F., Forster, Martin D., Diamantis, Nikolaos, Rulach, Robert, Greystoke, Alastair, Asghar, Uzma, Rata, Mihaela, Anderson, Stephanie, Bachmann, Felix, Hannah, Alison, Kaindl, Thomas, Lane, Heidi A., Larger, Patrice J., Schmitt-Hoffmann, Anne, Engelhardt, Marc, Tzankov, Alexandar, Plummer, Ruth, Lopez, Juanita

    प्रकाशित 2020
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  19. 19
    A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer

    A randomized phase 2 trial of epigenetic priming with guadecitabine and carboplatin in platinum-resistant, recurrent ovarian cancer द्वारा Oza, Amit, Matulonis, Ursula, Alvarez Secord, Angeles, Roman, Lynda, Blagden, Sarah, Banerjee, Susana, Nemunaitis, John, McGuire, William, Ghamande, Sharad, Birrer, Michael, Fleming, Gini F, Jennifer Markham, Merry, Hirte, Hal, Provencher, Diane, Basu, Bristi, Kristeleit, Rebecca, Armstrong, Deborah, Schwartz, Benjamin, Braly, Patricia, Hall, Geoffrey, Nephew, Kenneth P., Jueliger, Simone, Oganesian, Aram, Naim, Sue, Hao, Yong, Keer, Harold, Azab, Mohammad, Matei, Daniela

    प्रकाशित 2019
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:
  20. 20
    The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre

    The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy’s Cancer Centre द्वारा Russell, Beth, Moss, Charlotte, Tsotra, Eirini, Gousis, Charalampos, Josephs, Debra, Enting, Deborah, Karampera, Christina, Khan, Muhammad, Roca, Jose, Sita-Lumsden, Ailsa, Owczarczyk, Kasia, Wylie, Harriet, Haire, Anna, Smith, Daniel, Zaki, Kamarul, Swampillai, Angela, Lei, Mary, Manik, Vishal, Michalarea, Vasiliki, Kristeleit, Rebecca, Mera, Anca, Sawyer, Elinor, Flanders, Lucy, De Francesco, Irene, Papa, Sophie, Ross, Paul, Spicer, James, Dann, Bill, Jogia, Vikash, Shaunak, Nisha, Kristeleit, Hartmut, Rigg, Anne, Montes, Ana, Van Hemelrijck, Mieke, Dolly, Saoirse

    प्रकाशित 2022
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    मूलपाठ
    सूची में सहेजें
    में बचाया:

खोज साधन: